
    
      Masking: Double-blind for BMS-6630368 treatment groups until the Week 24 Primary Endpoint
      analysis, then open label. The reference groups is all open-label.

      Arms: 5 (4 BMS-663068 treatment groups and 1 reference group)

      Intervention Model: Parallel (with unblinding after the Week 24 primary endpoint analysis)
    
  